Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP1238351.RAfxw3GWNnFVfM9fhovClKpH1xoAqrs3Q3zBz_3q45euI130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP1238351.RAfxw3GWNnFVfM9fhovClKpH1xoAqrs3Q3zBz_3q45euI130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP1238351.RAfxw3GWNnFVfM9fhovClKpH1xoAqrs3Q3zBz_3q45euI130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP1238351.RAfxw3GWNnFVfM9fhovClKpH1xoAqrs3Q3zBz_3q45euI130_provenance.
- NP1238351.RAfxw3GWNnFVfM9fhovClKpH1xoAqrs3Q3zBz_3q45euI130_assertion description "[Combining valosin-containing protein (VCP) inhibition and suberanilohydroxamic acid (SAHA) treatment additively enhances the folding, trafficking, and function of epilepsy-associated ?-aminobutyric acid, type A (GABAA) receptors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1238351.RAfxw3GWNnFVfM9fhovClKpH1xoAqrs3Q3zBz_3q45euI130_provenance.
- NP1238351.RAfxw3GWNnFVfM9fhovClKpH1xoAqrs3Q3zBz_3q45euI130_assertion evidence source_evidence_literature NP1238351.RAfxw3GWNnFVfM9fhovClKpH1xoAqrs3Q3zBz_3q45euI130_provenance.
- NP1238351.RAfxw3GWNnFVfM9fhovClKpH1xoAqrs3Q3zBz_3q45euI130_assertion SIO_000772 25406314 NP1238351.RAfxw3GWNnFVfM9fhovClKpH1xoAqrs3Q3zBz_3q45euI130_provenance.
- NP1238351.RAfxw3GWNnFVfM9fhovClKpH1xoAqrs3Q3zBz_3q45euI130_assertion wasDerivedFrom befree-2016 NP1238351.RAfxw3GWNnFVfM9fhovClKpH1xoAqrs3Q3zBz_3q45euI130_provenance.
- NP1238351.RAfxw3GWNnFVfM9fhovClKpH1xoAqrs3Q3zBz_3q45euI130_assertion wasGeneratedBy ECO_0000203 NP1238351.RAfxw3GWNnFVfM9fhovClKpH1xoAqrs3Q3zBz_3q45euI130_provenance.
- befree-2016 importedOn "2016-02-19" NP1238351.RAfxw3GWNnFVfM9fhovClKpH1xoAqrs3Q3zBz_3q45euI130_provenance.